Skip To Main Content
Linan Yin on Muck Rack

Linan Yin

As seen in: Frontiers, Frontiers in Immunology, Dove Medical Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Linan

Contact Linan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Combination of locoregional and systemic therapy for hepatocellular carcinoma with portal vein tumor thrombus: a real-world retrospective study

|
By Xunbo Hou, Linan Yin, Ruibao Liu, Qiannan Xu, Yingchen Li, Bowen Liu, Xuesong Mike Liu
| Frontiers
Abstract Background: The optimal treatment strategy for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains undefined. Although combinations of locoregional therapies—such as transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC)—with systemic agents (tyrosine kinase inhibitors [TKIs] and PD-1 inhibitors) show promise, direct comparative evidence among different regimens remains limited.
Open in Who Shared Issue with article?

Frontiers | Correction: TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study

|
By Linan Yin, Weihang Li, Wencheng D. Shao, Xunbo Hou, Bowen Liu, Xuesong Mike Liu, Ruibao Liu, Peng Huang
| Frontiers in Immunology
CORRECTION article Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1745867 Author “Peng Huang” was erroneously assigned as corresponding author. The correct corresponding author is “Peng Huang and Ruibao Liu”. The original version of this article has been updated. Publisher’s note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.
Open in Who Shared View Duplicates (3) Issue with article?

Frontiers | TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study

|
By Weihang Li, Wencheng D. Shao, Bowen Liu, Xuesong Mike Liu, Ruibao Liu, Peng Huang, Linan Yin, Xunbo Hou
| Frontiers in Immunology
1 Introduction Hepatocellular carcinoma is the sixth most common malignancy globally and the third leading cause of cancer-related mortality, with an estimated annual incidence exceeding 800,000 new cases (1). This malignancy, predominantly arising in the context of chronic liver diseases such as hepatitis B, hepatitis C, or cirrhosis, poses a significant global health challenge (2).
Open in Who Shared Issue with article?
See all 4 articles